Immunization, measles in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD): Immunization, measles was 83.6% in 2024. ▲ Rising
Immunization, measles in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD), 1980–2024
Source: World Health Organization (WHO). Measured in % of children ages 12-23 months.
Analysis
In 2024, immunization, measles in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) stood at 83.6%. That is the highest value across all 45 years on record.
The figure is up 0.2% on the previous year and up 5.8% over ten years.
Over the whole period, immunization, measles in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) peaked at 83.6% in 2024 and was at its lowest, 15.6%, in 1980.
Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 29th of 47 groups on this measure, in the middle of the range.
The long-run direction has been consistently rising across the 45 years of available data.
Immunization, measles in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD), year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1980 | 15.6% | — |
| 1981 | 17.3% | +10.9% |
| 1982 | 21.6% | +25.2% |
| 1983 | 25.3% | +17.1% |
| 1984 | 32.7% | +29.2% |
| 1985 | 50.3% | +53.9% |
| 1986 | 53.2% | +5.8% |
| 1987 | 56.0% | +5.1% |
| 1988 | 65.0% | +16.1% |
| 1989 | 66.3% | +2.1% |
| 1990 | 68.6% | +3.4% |
| 1991 | 67.9% | -1.0% |
| 1992 | 69.4% | +2.2% |
| 1993 | 69.1% | -0.4% |
| 1994 | 69.4% | +0.5% |
| 1995 | 67.4% | -2.9% |
| 1996 | 69.5% | +3.2% |
| 1997 | 69.4% | -0.2% |
| 1998 | 71.9% | +3.6% |
| 1999 | 72.4% | +0.8% |
| 2000 | 72.4% | +0.0% |
| 2001 | 73.4% | +1.4% |
| 2002 | 72.8% | -0.8% |
| 2003 | 73.7% | +1.2% |
| 2004 | 75.0% | +1.7% |
| 2005 | 74.5% | -0.6% |
| 2006 | 74.0% | -0.7% |
| 2007 | 73.6% | -0.4% |
| 2008 | 73.4% | -0.3% |
| 2009 | 74.5% | +1.5% |
| 2010 | 75.1% | +0.8% |
| 2011 | 76.2% | +1.4% |
| 2012 | 76.0% | -0.3% |
| 2013 | 78.4% | +3.2% |
| 2014 | 79.0% | +0.7% |
| 2015 | 80.5% | +1.9% |
| 2016 | 82.0% | +1.9% |
| 2017 | 81.6% | -0.4% |
| 2018 | 82.0% | +0.5% |
| 2019 | 82.1% | +0.1% |
| 2020 | 82.4% | +0.3% |
| 2021 | 80.3% | -2.5% |
| 2022 | 81.6% | +1.6% |
| 2023 | 83.4% | +2.2% |
| 2024 | 83.6% | +0.2% |
Biggest year-on-year movements
Years where Immunization, measles in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 1985 | +53.9% | 32.7% | 50.3% |
| 1984 | +29.2% | 25.3% | 32.7% |
| 1982 | +25.2% | 17.3% | 21.6% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1980s | 40.3% | 15.6% | 66.3% | 10 |
| 1990s | 69.5% | 67.4% | 72.4% | 10 |
| 2000s | 73.7% | 72.4% | 75.0% | 10 |
| 2010s | 79.3% | 75.1% | 82.1% | 10 |
| 2020s | 82.2% | 80.3% | 83.6% | 5 |
Countries ranked near Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
- 31 Antigua and Barbuda 97.0% compare
- 31 Bhutan 97.0% compare
- 31 Botswana 97.0% compare
- 31 Egypt 97.0% compare
- 31 Iceland 97.0% compare
- 31 India 97.0% compare
- 31 South Korea 97.0% compare
- 31 Nepal 97.0% compare
- 31 Russia 97.0% compare
- 31 Rwanda 97.0% compare
- 31 Seychelles 97.0% compare
- 31 Singapore 97.0% compare
- 31 Spain 97.0% compare
- 31 Tuvalu 97.0% compare
- 31 Uruguay 97.0% compare
More health data for Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, male, annual growth rate 3.1 % change on previous year (2025)
- Population ages 40-44, female, per capita 0.0305 units per person (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate 3.2 % change on previous year (2025)
- Population ages 35-39, male, per capita 0.0351 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, annual growth rate 1.48 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0341 units per person (2025)
- Population ages 30-34, female, annual growth rate 0.471 % change on previous year (2025)
All data for Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) →
Frequently asked questions
- What is immunization, measles in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- Immunization, measles in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) was 83.6% in 2024, according to World Health Organization (WHO).
- What is the highest immunization, measles recorded in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- The highest recorded value was 83.6% in 2024.
- What is the lowest immunization, measles recorded in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- The lowest recorded value was 15.6% in 1980.
- How does Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) rank for immunization, measles?
- Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 29th out of 47 groups with data for 2024.
- Is immunization, measles rising or falling in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- Over the last ten years it is up 5.8%. The long-run trend across the full record is rising.
- Where does this Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) data come from?
- The figures come from World Health Organization (WHO), published as part of Immunization, measles (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 45 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.